21:24 EDT Cathie Wood’s ARK Investment bought 151.9K shares of Crispr Therapeutics
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Citi sees approval for Crispr Therapeutics, keeps $70 price target
- CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
- Crispr Therapeutics announces completion of FDA panel meeting for exa-cel
- Crispr Therapeutics announces NASDAQ halted trading of stock ahead of meeting
- CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)